Covid, Ema: “We need boosters against Omicron, but unsustainable long-term recalls”

How to face the future? A report on anti-Covid vaccines, on the issue of efficacy against the Omicron variant of Sars-CoV-2, but also on which shield products will be needed to manage Covid-19 in the long term. These are the points now under discussion among drug agencies around the world, including the European EMA.

They warn: “Looking at the data on the impact of Omicron,” “it is becoming increasingly clear that a booster dose is needed to extend vaccine protection.”